Cours Novavax, Inc. Nasdaq
Actions
US6700021040
Recherche biotechnologique et médicale
CA 2024 * | 952 M 864 M | CA 2025 * | 586 M 532 M | Capitalisation | 1,84 Md 1,67 Md |
---|---|---|---|---|---|
Résultat net 2024 * | 18 M 16,34 M | Résultat net 2025 * | -116 M -105 M | VE / CA 2024 * | 1,05 x |
Trésorerie nette 2024 * | 837 M 760 M | Trésorerie nette 2025 * | 704 M 639 M | VE / CA 2025 * | 1,94 x |
PER 2024 * |
206
x | PER 2025 * |
-23,8
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 94,12% |
Dernier transcript sur Novavax, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/01/23 |
John Trizzino
PSD | President | 64 | 10/03/14 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/08/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/10/22 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/11/20 |
David Mott
BRD | Director/Board Member | 58 | 16/06/20 |
Varia. 1 janv. | Capi. | |
---|---|---|
+26,37% | 48,16 Md | |
-1,01% | 41,73 Md | |
+42,66% | 41,03 Md | |
-5,31% | 28,77 Md | |
+9,34% | 25,59 Md | |
-21,69% | 18,96 Md | |
+6,23% | 12,92 Md | |
+26,99% | 12,03 Md | |
-3,38% | 11,77 Md |